Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 11/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11934657 | 1.00 | SLC29A1 (0.42) | SLC29A1LMNATHRBMTORMDM2 | |
| SCHEMBL11934658 | 0.91 | SLC29A1 (0.39) | SLC29A1LMNARAB9ACYP3A4PKM | |
| SCHEMBL29446054 | 0.91 | LMNA (0.49) | SLC29A1LMNATHRBMTORMDM2 | |
| SCHEMBL14084325 | 0.91 | LMNA (0.49) | SLC29A1LMNATHRBMTORMDM2 | |
| SCHEMBL14534827 | 0.91 | LMNA (0.49) | SLC29A1LMNATHRBMTORMDM2 | |
| SCHEMBL29703 | 0.91 | LMNA (0.49) | SLC29A1LMNATHRBMTORMDM2 | |
| SCHEMBL1062447 | 0.91 | LMNA (0.49) | SLC29A1LMNATHRBMTORMDM2 | |
| SCHEMBL13205010 | 0.85 | SLC6A2 (0.38) | LMNASMN1; SMN2 | |
| SCHEMBL13714345 | 0.85 | SLC6A2 (0.38) | LMNASMN1; SMN2 | |
| SCHEMBL11934654 | 0.83 | SLC6A2 (0.33) | SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227188-B2 | Enhancement of influenza gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110033859-A1 | RNAi INHIBITION OF INFLUENZA VIRUS REPLICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |